Formycon anti-PD1 antibody formulations

The EPO published Formycon AG's patent application EP4359001A1 for stable anti-PD1 antibody formulations, classified under IPC codes including A61K39/395, C07K16/28, and A61P35/00. The formulations include various stabilizers such as polysorbate, poloxamer, sucrose, and histidine buffers. Designated states cover all EU member states plus other European Patent Convention countries.

For IP and legal professionals, this patent publication establishes prior art as of the filing date and begins the 18-month publication window before potential opposition. Competitors developing PD-1 antibody formulations should conduct freedom-to-operate analyses. No compliance actions are required from regulatory or compliance teams unless involved in biologics patent strategy.